Swiss National Bank Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Swiss National Bank acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 67,400 shares of the biotechnology company’s stock, valued at approximately $930,000. Swiss National Bank owned 0.15% of Capricor Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC bought a new stake in Capricor Therapeutics during the 4th quarter valued at $78,000. New York State Common Retirement Fund grew its position in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $161,000. Sassicaia Capital Advisers LLC acquired a new position in shares of Capricor Therapeutics in the third quarter valued at about $192,000. Finally, SG Americas Securities LLC increased its holdings in Capricor Therapeutics by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,552 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $11.50 on Friday. The stock has a market cap of $522.91 million, a PE ratio of -10.85 and a beta of 4.10. The stock’s fifty day moving average is $14.00 and its two-hundred day moving average is $14.92. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, research analysts expect that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on CAPR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.